Celltrion, Inc. (068270.KS)
KRW 162600.0
(0.81%)
KRW 162600.0
(0.81%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 1890.42 Billion KRW | 138.59% |
| 2022 | 792.33 Billion KRW | 6.45% |
| 2021 | 744.35 Billion KRW | -3.88% |
| 2020 | 774.4 Billion KRW | 56.33% |
| 2019 | 495.36 Billion KRW | -4.1% |
| 2018 | 516.55 Billion KRW | -19.4% |
| 2017 | 640.91 Billion KRW | -5.6% |
| 2016 | 678.94 Billion KRW | -14.69% |
| 2015 | 795.86 Billion KRW | -5.87% |
| 2014 | 845.45 Billion KRW | 12.81% |
| 2013 | 749.46 Billion KRW | 25.11% |
| 2012 | 599.02 Billion KRW | 43.7% |
| 2011 | 416.86 Billion KRW | 51.59% |
| 2010 | 274.99 Billion KRW | 10.6% |
| 2009 | 248.64 Billion KRW | 7.21% |
| 2008 | 231.93 Billion KRW | 750.69% |
| 2007 | 27.26 Billion KRW | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 2180.28 Billion KRW | 15.33% |
| 2024 Q2 | 2174.42 Billion KRW | -0.27% |
| 2023 Q2 | 840.23 Billion KRW | 7.62% |
| 2023 Q3 | 889.74 Billion KRW | 5.89% |
| 2023 Q1 | 780.74 Billion KRW | -1.46% |
| 2023 Q4 | 1890.42 Billion KRW | 112.47% |
| 2023 FY | 1890.42 Billion KRW | 138.59% |
| 2022 Q3 | 810.92 Billion KRW | 1.34% |
| 2022 Q4 | 792.33 Billion KRW | -2.29% |
| 2022 Q2 | 800.16 Billion KRW | 40.5% |
| 2022 FY | 792.33 Billion KRW | 6.45% |
| 2022 Q1 | 569.53 Billion KRW | -23.49% |
| 2021 Q3 | 753.37 Billion KRW | 1.2% |
| 2021 Q4 | 744.35 Billion KRW | -1.2% |
| 2021 Q1 | 755.15 Billion KRW | -2.49% |
| 2021 Q2 | 744.43 Billion KRW | -1.42% |
| 2021 FY | 744.35 Billion KRW | -3.88% |
| 2020 FY | 774.4 Billion KRW | 56.33% |
| 2020 Q2 | 532.37 Billion KRW | 6.8% |
| 2020 Q1 | 498.47 Billion KRW | 0.63% |
| 2020 Q4 | 774.4 Billion KRW | 41.32% |
| 2020 Q3 | 547.96 Billion KRW | 2.93% |
| 2019 Q3 | 498.87 Billion KRW | -4.68% |
| 2019 Q2 | 523.39 Billion KRW | 1.08% |
| 2019 FY | 495.36 Billion KRW | -4.1% |
| 2019 Q1 | 517.8 Billion KRW | 0.24% |
| 2019 Q4 | 495.36 Billion KRW | -0.7% |
| 2018 Q1 | 632.71 Billion KRW | -1.28% |
| 2018 Q4 | 516.55 Billion KRW | -6.41% |
| 2018 Q3 | 551.93 Billion KRW | -6.97% |
| 2018 FY | 516.55 Billion KRW | -19.4% |
| 2018 Q2 | 593.3 Billion KRW | -6.23% |
| 2017 FY | 640.91 Billion KRW | -5.6% |
| 2017 Q2 | 652.48 Billion KRW | -3.65% |
| 2017 Q3 | 646.23 Billion KRW | -0.96% |
| 2017 Q4 | 640.91 Billion KRW | -0.82% |
| 2017 Q1 | 677.17 Billion KRW | -0.26% |
| 2016 Q3 | 676.35 Billion KRW | -1.02% |
| 2016 Q4 | 678.94 Billion KRW | 0.38% |
| 2016 Q1 | 631.21 Billion KRW | -20.69% |
| 2016 FY | 678.94 Billion KRW | -14.69% |
| 2016 Q2 | 683.29 Billion KRW | 8.25% |
| 2015 Q4 | 795.86 Billion KRW | -1.34% |
| 2015 Q3 | 806.64 Billion KRW | -0.21% |
| 2015 FY | 795.86 Billion KRW | -5.87% |
| 2015 Q2 | 808.35 Billion KRW | -7.97% |
| 2015 Q1 | 878.32 Billion KRW | 3.89% |
| 2014 Q3 | 830.56 Billion KRW | -1.7% |
| 2014 Q2 | 844.94 Billion KRW | 1.59% |
| 2014 FY | 845.45 Billion KRW | 12.81% |
| 2014 Q4 | 845.45 Billion KRW | 1.79% |
| 2014 Q1 | 831.71 Billion KRW | 10.97% |
| 2013 FY | 749.46 Billion KRW | 25.11% |
| 2013 Q4 | 749.46 Billion KRW | -3.46% |
| 2013 Q3 | 776.34 Billion KRW | -1.93% |
| 2013 Q2 | 791.63 Billion KRW | -8.04% |
| 2013 Q1 | 860.89 Billion KRW | 43.72% |
| 2012 Q4 | 599.02 Billion KRW | 0.0% |
| 2012 Q1 | 450.86 Billion KRW | 0.0% |
| 2012 FY | 599.02 Billion KRW | 43.7% |
| 2011 Q1 | 290.21 Billion KRW | 5.53% |
| 2011 FY | 416.86 Billion KRW | 51.59% |
| 2011 Q3 | 398.66 Billion KRW | 15.81% |
| 2011 Q2 | 344.23 Billion KRW | 18.62% |
| 2010 Q1 | 251.87 Billion KRW | 1.3% |
| 2010 Q4 | 274.99 Billion KRW | -1.87% |
| 2010 FY | 274.99 Billion KRW | 10.6% |
| 2010 Q3 | 280.24 Billion KRW | 11.21% |
| 2010 Q2 | 252 Billion KRW | 0.05% |
| 2009 Q3 | 226.47 Billion KRW | 5.52% |
| 2009 Q2 | 214.61 Billion KRW | -15.52% |
| 2009 Q1 | 254.03 Billion KRW | 9.53% |
| 2009 FY | 248.64 Billion KRW | 7.21% |
| 2009 Q4 | 248.64 Billion KRW | 9.79% |
| 2008 Q3 | 253.39 Billion KRW | 1670.73% |
| 2008 Q1 | 20.4 Billion KRW | 0.0% |
| 2008 FY | 231.93 Billion KRW | 750.69% |
| 2008 Q2 | 14.31 Billion KRW | -29.86% |
| 2008 Q4 | 231.93 Billion KRW | -8.47% |
| 2007 Q3 | 16.44 Billion KRW | -0.21% |
| 2007 Q1 | 13.09 Billion KRW | 0.0% |
| 2007 Q2 | 16.47 Billion KRW | 25.78% |
| 2007 FY | 27.26 Billion KRW | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| ORIENT BIO Inc. | 3.03 Billion KRW | -62090.786% |
| Green Cross Holdings Corporation | 1280.16 Billion KRW | -47.67% |
| Green Cross Holdings Corporation | 724.02 Billion KRW | -161.1% |
| Pharmicell Co., Ltd. | 3.02 Billion KRW | -62336.75% |
| Green Cross Corporation | 724.02 Billion KRW | -161.1% |
| GeneOne Life Science, Inc. | 17.15 Billion KRW | -10916.699% |
| Samsung Biologics Co.,Ltd. | 1909.33 Billion KRW | 0.991% |
| SK bioscience Co.,Ltd. | 20.57 Billion KRW | -9088.605% |
| SK Biopharmaceuticals Co., Ltd. | 178.05 Billion KRW | -961.735% |
| Prestige BioPharma Limited | 89.66 Billion KRW | -2008.265% |